Cytokinetics (NASDAQ:CYTK) Earns Buy Rating from HC Wainwright
Cytokinetics (NASDAQ:CYTK – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC ...
Zacks.com on MSN6h
CYTK Stock Rises as Enrollment Begins in Phase II Heart Failure Study
Cytokinetics stock up as the company initiates patient enrollment in its mid-stage study of pipeline candidate, CK-586, for treating heart failure patients.
Buy Rating for Esperion Based on Strong Clinical Data and Market Adoption of NEXLETOL and NEXLIZET
JMP Securities analyst Jason Butler reiterated a Buy rating on Esperion (ESPR – Research Report) today and set a price target of $7.00.Invest ...
Guggenheim raises Immunovant stock target to $46, maintains Buy
Guggenheim Securities updated their outlook on Immunovant (NASDAQ:IMVT) shares, raising the price target from $44.00 to $46.00 while maintaining a Buy rating on the stock. Currently trading at $23.23, ...
Elevance Health Posts Q4 Profit Despite Medicaid Drop, Rising Costs; Hikes Dividend 5%
Elevance Health Q4 revenues hit $45 billion, driven by premium growth and acquisitions. 2025 EPS guidance is $34.15-$34.85, with a $1.71 dividend declared.
Allbirds (NASDAQ:BIRD) Price Target Lowered to $8.00 at Morgan Stanley
Allbirds (NASDAQ:BIRD – Get Free Report) had its target price lowered by investment analysts at Morgan Stanley from $12.00 to $8.00 in a research note issued to investors on Tuesday,Benzinga reports.